Cyberonics VNS Therapy
This article was originally published in The Gray Sheet
Executive Summary
Panel-track, 87-volume PMA supplement for use of the vagus nerve stimulation system for adjunctive, drug treatment-resistant depression is submitted to FDA. The firm plans to present pivotal D-02 trial data in May 2004 at the American Psychiatric Association meeting and gain approval by October 2004 with expedited review (1"The Gray Sheet" July 28, 2003, p. 18). Separately, Cyberonics announces Nov. 5 a 12% jump in sales to $29.3 mil., and near tripling of earnings to $3.8 mil. in the fiscal second quarter (ended Oct. 24)...
You may also be interested in...
Cyberonics Expects VNS Will Capture 4% Of U.S. Depression Market By 2010
Cyberonics anticipates FDA approval of a depression indication for its VNS Therapy vagus nerve stimulation system by October 2004
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.